Safety of exercise training in multiple sclerosis: a protocol for an updated systematic review and meta-analysis

Safety of exercise training in multiple sclerosis: a protocol for an updated systematic review and meta-analysis

Abstract Background There has been an exponential growth in the number of clinical research studies regarding exercise training in multiple sclerosis, and literature reviews and meta-analyses have documented the many benefits of exercise training. This research further requires careful review for do...

Full description

Bibliographic Details
Main Authors:	Y. C. Learmonth, L. A. Pilutti, M. P. Herring, R. W. Motl, B. Chan, A. P. Metse
Format:	Article
Language:	English
Published:	BMC 2021-07-01
Series:	Systematic Reviews
Subjects:	Multiple sclerosis Exercise-training Relapse Adverse event Serious adverse event
Online Access:	https://doi.org/10.1186/s13643-021-01751-0

Similar Items

The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis
by: Hou H, et al.
Published: (2019-05-01)

Ethics of safety reporting of a clinical trial
by: Amrita Sil, et al.
Published: (2017-01-01)

Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial
by: Elizabeth C. James, et al.
Published: (2020-09-01)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
by: Bin Zhao, et al.
Published: (2018-10-01)

Individual risk of post-ivermectin serious adverse events in subjects infected with Loa loa
by: Cédric B. Chesnais, et al.
Published: (2020-11-01)

Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis
by: Silvia Boullosa-Lale, et al.
Published: (2021-03-01)

Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials
by: Sophie Marie Anne Effing, et al.
Published: (2020-08-01)

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
by: Trygve Holmøy, et al.
Published: (2019-08-01)

Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies
by: Antonio Bertolotto, et al.
Published: (2020-05-01)

Prevalence rate of spontaneously reported adverse events and determinants of serious adverse events amongst three outpatient care settings in ghana: findings and implications
by: Israel Abebrese Sefah, et al.
Published: (2021-01-01)

Monitoring adverse social and medical events in public health trials: assessing predictors and interpretation against a proposed model of adverse event reporting
by: Gwenllian Moody, et al.
Published: (2019-12-01)

Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States
by: Jara M, et al.
Published: (2015-12-01)

The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study
by: Alexandra W. Elias, et al.
Published: (2017-06-01)

Beta-interferons in multiple sclerosis: A single center experience in India
by: Gupta Salil, et al.
Published: (2010-01-01)

Complete Remission of Relapsed Hodgkin’s Lymphoma following Brentuximab Vedotin and Gemcitabine Combination Therapy with Severe Hypotension as Possible Treatment-Related Adverse Event: A Case Report
by: Ibnu Purwanto, et al.
Published: (2020-03-01)

Pharmacovigilance for clinical trials in India: Current practice and areas for reform
by: Ballari Brahmachari, et al.
Published: (2011-01-01)

OPENCRONIC Study. Knowledge and Experiences of Spanish Patients and Carers about Chronic Disease
by: Emilio Casariego, et al.
Published: (2018-12-01)

Characterization and preventability of adverse drug events as cause of emergency department visits: a prospective 1-year observational study
by: Ivan Lo Giudice, et al.
Published: (2019-04-01)

Behavioral, Psychiatric, and Cognitive Adverse Events in Older Persons Treated with Glucocorticoids
by: Ciro Manzo, et al.
Published: (2018-08-01)

Convulsive syndrome in the post-vaccination period: is there a connection with the vaccine?
by: E. P. Nacharova, et al.
Published: (2021-01-01)

Adverse effects of psychotherapy: protocol for a systematic review and meta-analysis
by: Rahel Klatte, et al.
Published: (2018-09-01)

Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis
by: Annette Kolb-Mäurer, et al.
Published: (2015-07-01)

What should we report? Lessons learnt from the development and implementation of serious adverse event reporting procedures in non-pharmacological trials in palliative care
by: Lesley Dunleavy, et al.
Published: (2021-01-01)

Everolimus versus sirolimus for angiomyolipoma associated with tuberous sclerosis complex: a multi-institutional retrospective study in China
by: Cong Luo, et al.
Published: (2021-07-01)

Possible Causes of and Measures to Minimise Risks of Abscesses Following DTP Vaccination
by: N. V. Tereshkina, et al.
Published: (2021-03-01)

Pharmacovigilance Analysis of Serious Adverse Events Reported for Biologic Response Modifiers Used as Prophylaxis against Transplant Rejection: a Real-World Postmarketing Experience from the US FDA Adverse Event Reporting System (FAERS)
by: A. K. Ali
Published: (2013-04-01)

Metastatic kidney cancer: Choice of first-line therapy
by: B. Ya. Alekseev
Published: (2014-11-01)

Efficacy of Lenalidomide plus Low-Dose Dexamethasone in Thai Patients with Relapsed and/or Refractory Multiple Myeloma
by: Chutima Kunacheewa, et al.
Published: (2021-04-01)

Metastatic kidney cancer: Choice of first-line therapy
by: B. Ya. Alekseev
Published: (2014-11-01)

Methodological Flaws, Conflicts of Interest, and Scientific Fallacies: Implications for the Evaluation of Antidepressants’ Efficacy and Harm
by: Michael P. Hengartner
Published: (2017-12-01)

Can the Number of Radiofrequency Activations Predict Serious Adverse Events after Bronchial Thermoplasty? A Retrospective Case-Control Study
by: Shota Yamamoto, et al.
Published: (2019-11-01)

Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group
by: Irini Genitsaridi, et al.
Published: (2020-09-01)

Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report
by: Aija Zuleron Myro, et al.
Published: (2018-11-01)

MANAGEMENT OF ADVERSE EVENTS IN THE HOSPITAL
by: Danguolė Jankauskienė, et al.
Published: (2019-12-01)

The characteristics and trend of adverse events following immunization reported by information system in Jiangsu province, China, 2015–2018
by: Ran Hu, et al.
Published: (2021-07-01)

The Rise of Patient Safety-II: Should We Give Up Hope on Safety-I and Extracting Value From Patient Safety Incidents?; Comment on “False Dawns and New Horizons in Patient Safety Research and Practice”
by: Andrew Carson-Stevens, et al.
Published: (2018-07-01)

Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis
by: Cui Y, et al.
Published: (2018-11-01)

Self-reported dietary supplement use in deployed United States service members pre-deployment vs. during deployment, Afghanistan, 2013–2014
by: Shawn M. Varney, et al.
Published: (2017-10-01)

Seeking adverse effects in systematic reviews of orthodontic interventions: protocol for a cross-sectional study
by: Pauline A. J. Steegmans, et al.
Published: (2019-04-01)

Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis
by: Nuttall E, et al.
Published: (2019-07-01)

Cannot write session to /tmp/vufind_sessions/sess_v27jhjvdap0486pul2gj5uts9c